| Name | Title | Contact Details |
|---|---|---|
David Lafond |
Vice-President of Innovation and Technology | Profile |
We are a rare disease therapeutics company leading with science to make life-changing therapeutics available to patients with significant unmet needs. We involve key thought leaders, physicians, patients, care partners, and advocacy groups in all of our clinical and regulatory development strategies. With a keen understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed. By following the data without bias, our transparent narratives and common-sense perspective have successfully overcome complex development challenges to make much-needed therapies available to patients. Nimble and dauntless, we push boundaries beyond what is thought to be possible and advance new therapies that have the potential to bring meaningful improvement to patients lives.
Mateon Therapeutics/Oncotelic is developing TGF-beta therapies and Apomorphine for Parkinson, ED, FSD. https://t.co/nReUVgPvhc. $OTLC
Leading the translation of RNA-modifying protein (RMP) biology into promising new therapies for cancer.
Astellas Venture Capital is a Menlo Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alfa Scientific Designs, Inc is a Poway, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.